Watch ENSC. Know when insiders buy.
One email the day a filing lands. Free.
ENSC
Ensysce Biosciences, Inc.
0.49
−0.03 −5.62%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $9.5MP/E —DIV YIELD —FCF YIELD —REV TTM $4.5M −39.3%NET INCOME −$12.6MNET CASH —52W 0.25 – 2.57SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.2M | −15.1% | — | −$2.6M | −$2.6M | — | -0.20 | −$2M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $961K | −27.2% | — | −$3.6M | −$3.6M | — | -0.52 | −$3.5M | — | — | May 15 |
| Q4 2025 · Dec 31derived | $1.9M | +44.4% | — | −$2.8M | −$2.8M | — | -0.56 | −$1.5M | $0 | −$1.5M | Mar 30 |
| Q3 2025 · Sep 30 | $493K | −85.6% | — | −$3.7M | −$3.7M | −663.5% | -1.29 | −$1.9M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | $1.4M | +654.4% | — | −$1.8M | −$1.7M | — | -0.79 | −$2.7M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | $1.3M | +331.7% | — | −$2M | −$1.9M | — | -1.39 | −$1.7M | — | — | May 15 |
| Q4 2024 · Dec 31derived | $1.3M | +153.1% | — | −$3.6M | −$3.6M | — | -2.93 | −$764K | — | — | Mar 30 |
| Q3 2024 · Sep 30 | $3.4M | +685.3% | — | $645K | $662K | — | 1.00 | −$1M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | $182K | — | — | −$2M | −$2M | — | -3.35 | −$2.3M | — | — | Aug 13 |
| Q1 2024 · Mar 31 | $306K | — | — | −$1.8M | −$3.1M | — | -8.21 | −$3.4M | — | — | May 13 |
| Q4 2023 · Dec 31derived | $515K | — | — | −$3.2M | −$3.5M | — | -67.08 | −$1.8M | — | — | Mar 10 |
| Q3 2023 · Sep 30 | $435K | — | — | −$2.7M | −$2.7M | — | -0.87 | −$2.3M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $5.1M | — | −$10.2M | −$10.2M | -200.8% | -3.98 | −$7.8M | $124K | −$7.9M | — | — |
| FY2024 · to Dec 31 | $5.2M | — | −$6.7M | −$8M | -153.3% | -11.45 | −$7.5M | — | — | — | — |
| FY2023 · to Dec 31 | $2.2M | — | −$10.7M | −$10.6M | -476.4% | -70.40 | −$10.8M | — | — | — | — |
| FY2022 · to Dec 31 | $2.5M | — | −$24.2M | −$24.2M | -959.3% | -139.42 | −$17.9M | — | — | — | — |
| FY2021 · to Dec 31 | $3.5M | — | −$19.9M | −$29.1M | -825.4% | -1.48 | −$8.2M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$1.6M | $4.3M | — | 0.00 | −$1.2M | — | — | $184.8M | — |
Every number comes from Ensysce Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.